:
Febuxostat is a novel, orally administered, powerful, non-purine, xanthine oxidase inhibitor used for treating gout and ceaseless tophaceous gout. The drug exhibits low bioavailability (about 49%) which is ascribed to its dissolution rate limited absorption. The aim of the current work was to provide a novel strategy to improve the dissolution profile and thus, bioavailability of Febuxostat. Formulation of fast dissolving tablets (FDT) is anticipated to provide immediate release of drug, which in turn, will improve its dissolution profile to provide the initial surge in plasma concentration required in acute gout attack. Incorporation of co-processed excipients in a tablet is known to improve the compressibility and disintegration characteristics of the tablets, which, in turn, result in enhanced in vitro drug release and improved bioavailability. A combination of crospovidone (it rapidly wicks saliva into the tablet to create the volume development and hydrostatic weight important to give quick disintegration) and microcrystalline cellulose (highly compressible ingredient with good wicking and absorbing capacity) was, therefore, used as co-processed excipients. The tablets were prepared by direct compression technique with the application of a 32 randomized full factorial design. The prepared tablets were able to release more than 80% of the drug within 10 minutes of the start of dissolution testing and were able to show better drug release profile in comparison to available marketed formulation.